UiPath Inc.
NYSE:PATHSoftware - Infrastructure
-$0.21 today
- Market cap
- $6.46B
- Beta
- 0.97
- P/E (TTM)
- 16.0
- EPS (TTM)
- $0.63
Volume 23.55M
Average 32.78M
PATH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
UiPath Inc.NYSE: PATH
Research & Development · Q2 FY2027 · quarter ended Jul 2026
Research & development declines year over year
Q2 FY2027 research & development of $83.39M fell 15.2% year over year, behind the -5.2% change in trailing-twelve-month research & development. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Research & development amounted to 23.9% of revenue in FY2026, down 2.7 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.2% toward the trailing-twelve-month pace of -5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 385.26M USD
- Year-over-year change
- +1.2%
- 4-year CAGR
- +8.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 385.26M | +1.2% |
| FY2025 | 2025-01-31 | 380.68M | +14.6% |
| FY2024 | 2024-01-31 | 332.1M | +16.2% |
| FY2023 | 2023-01-31 | 285.75M | +3.3% |
| FY2022 | 2022-01-31 | 276.66M | — |
Research & Development vs competitors
How PATH compares with its peers on the latest reported figures
- PATH's LTM Jul 2026 research & development of $368.32M is the 2nd highest of the 4 companies compared; the peer median is $321.38M.
- Its year-over-year change of -5.2% is the lowest of 4, against a peer median of +19.4%.
- Research & development amounts to 21.4% of revenue for PATH, versus a peer median of 22.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.26B | +19.4% | +18.7% | 22.1% | |
| LTM Jul 2026 | $368.32M | -5.2% | +10.5% | 21.4% | |
| LTM Sep 2026 | $321.38M | +4.3% | +2.0% | 18.4% | |
| LTM Sep 2026 | $189.33M | +20.3% | +7.3% | 22.5% | |
| Peer median (excluding PATH) | $321.38M | +19.4% | +7.3% | 22.1% | |
Competitors are the stored peer set for PATH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 892.25M | 1.06B | 1.31B | 1.43B | 1.61B |
| Cost of Revenue | 168.87M | 180.05M | 195.92M | 246.94M | 274.13M |
| Gross Profit | 723.38M | 878.53M | 1.11B | 1.18B | 1.34B |
| Gross Margin | 81.1% | 83.0% | 85.0% | 82.7% | 83.0% |
| Research & Development | 276.66M | 285.75M | 332.1M | 380.68M | 385.26M |
| Selling, General & Admin | 947.67M | 941.06M | 944.77M | 964.61M | 890.23M |
| Operating Expenses | 1.22B | 1.23B | 1.28B | 1.35B | 1.28B |
| Depreciation & Amortization | 14.71M | 18.72M | 22.6M | 17.23M | 16.97M |
| EBITDA | (496.18M) | (298.84M) | (53.22M) | (60.87M) | 117.6M |
| EBITDA Margin | -55.6% | -28.2% | -4.1% | -4.3% | 7.3% |
| Operating Income | (500.95M) | (348.28M) | (164.72M) | (162.57M) | 60.96M |
| Operating Margin | -56.1% | -32.9% | -12.6% | -11.4% | 3.8% |
| Interest Income | 3.55M | 27.96M | 57.13M | 49.42M | 48.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (9.94M) | 30.72M | 88.91M | 84.47M | 39.67M |
| Income Before Tax | (510.88M) | (317.56M) | (75.82M) | (78.1M) | 100.63M |
| Pre-Tax Margin | -57.3% | -30.0% | -5.8% | -5.5% | 6.2% |
| Income Tax Expense | 14.7M | 10.79M | 14.07M | (4.41M) | (181.7M) |
| Net Income | (525.59M) | (328.35M) | (89.88M) | (73.69M) | 282.33M |
| Net Margin | -58.9% | -31.0% | -6.9% | -5.2% | 17.5% |
| EPS (Basic) | (0.97) | (0.60) | (0.16) | (0.13) | 0.52 |
| EPS (Diluted) | (0.97) | (0.60) | (0.16) | (0.13) | 0.52 |
| Weighted Avg Shares | 541.23M | 548.02M | 563.86M | 559.93M | 538.13M |
| Weighted Avg Shares (Diluted) | 541.23M | 548.02M | 563.86M | 559.93M | 544.86M |
UiPath Inc.
NYSE:PATH
Intrinsic Alpha fair value
Locked
Current Price
$12.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.